Prostate Cancer - Results from #10

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival. March 20, 2023

Patient Perceptions of a Decision Support Tool for Men with Localized Prostate Cancer. March 20, 2023

Experiences of Men With Prostate Cancer Participating in a Clinical Pathway With a Supervised Group-based Exercise Program to Combat Androgen Deprivation-Induced Side Effects: A Qualitative Focus Group Study. March 20, 2023

Convolutional Neural Network Quantification of Gleason Pattern 4 and Association with Biochemical Recurrence in Intermediate Grade Prostate Tumors. March 20, 2023

Next Generation Radiotheranostics Promoting Precision Medicine. March 20, 2023

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer March 17, 2023

Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. March 17, 2023

Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach. March 17, 2023

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177 Lu-PSMA-617. A single-center prospective observational study. March 17, 2023

The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. March 17, 2023

MATCHING BRCA AND PROSTATE CANCER IN A PUBLIC HEALTH SYSTEM: REPORT OF THE ITALIAN SOCIETY FOR URO-ONCOLOGY (SIUrO) CONSENSUS PROJECT. March 17, 2023

Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer. March 16, 2023

Radial wave therapy does not improve early recovery of erectile function after nerve-sparing radical prostatectomy: a prospective trial. March 16, 2023

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. March 16, 2023

Are high-risk prostate cancer patients being treated equally? The impact of PSA. March 16, 2023

Feasibility and acceptability of remote symptom monitoring (RSM) in older adults during treatment for metastatic prostate cancer. March 16, 2023

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. March 15, 2023

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. March 15, 2023

Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective. March 15, 2023

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. March 15, 2023

Page 1 of 1287